S-Adenosylmethionine (SAMe) monotherapy for depression: an 8-week double-blind, randomised, controlled trial
Jerome Sarris, Jenifer Murphy, Con Stough, David Mischoulon, Chad Bousman, Patricia MacDonald, Laura Adams, Sonia Nazareth, Georgina Oliver, Lachlan Cribb, Karen Savage, Ranjit Menon, Suneel Chamoli, Michael Berk, Chee H Ng, Gerard J Byrne
Psychopharmacology | SPRINGER | Published : 2019
RATIONALE: Dysregulation of the one carbon cycle is documented in depression. Thereby, S-adenosylmethionine (SAMe), a one-carbon cycle nutraceutical compound with a favourable side effect profile, has a theoretical rationale for efficacy. However, further controlled studies are required to confirm SAMe's efficacy. OBJECTIVES: To test the efficacy of SAMe versus placebo in unmedicated DSM-5 diagnosed (major depressive disorder) (MDD) patients with mild-to-moderate levels of depressive symptoms. METHODS: We conducted an 8-week, double-blind, randomised controlled trial testing 800 mg/day of SAMe monotherapy versus placebo in 49 patients with MDD (Montgomery-Åsberg Depression Rating Scale [MADR..View full abstract
Awarded by National Health and Medical Research Council (NHMRC)
Awarded by NHMRC
This study is funded by a National Health and Medical Research Council (NHMRC) project grant (APP1048222), and is co-sponsored by FIT-BioCeuticals. Jerome Sarris is supported by an NHMRC Fellowship (APP1125000). Michael Berk is supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (APP1059660 and APP1156072). Study sponsors had no role in study design, in the collection and analysis of data, manuscript preparation, nor the decision to submit the paper for publication.